Adding Relacorilant To Nab-paclitaxel Prolongs Survival Compared with a Weekly Taxane in Patients with Platinum-Resistant Epithelial Ovarian Cancer By Ogkologos - June 23, 2025 589 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ROSELLA study Source RELATED ARTICLESMORE FROM AUTHOR Safety and Antitumour Activity of Setidegrasib in Patients with Previously Treated Advanced KRAS p.G12D-mutated NSCLC and PADC EMA Recommends Granting a Marketing Authorisation for Poherdy Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with Solid Cancers MOST POPULAR Inpatient Mammography May Help Solve Issue of Low Screening Rates, Especially... July 12, 2021 Targeted drug recommended to treat some advanced lung cancer patients November 25, 2021 “Your Stories” Podcast: Amplifying Patient Voices September 8, 2020 El cáncer en mi comunidad: Ampliar el acceso a las pruebas... September 1, 2020 Load more HOT NEWS ΚΑΡΚΙΝΟΣ ΘΥΜΟΥ ΑΔΕΝΑ (ΘΥΜΩΜΑ) Droplet Transmission vs. Airborne… What’s the difference? Development of Secondary T-Cell Cancers After the Use of CAR T-Cells... EMA Recommends Granting a Marketing Authorisation for Tebentafusp
